United States Patent 12,233,038: Elafibranor PBC Claims, Exclusivity, and Patent Landscape

U.S. Patent No. 12,233,038 covers a narrow method-of-use regimen for treating primary biliary cholangitis with oral elafibranor at 70–130 mg per administration, particularly 80 mg once daily, with alkaline phosphatase normalization as the claimed therapeutic result. The claims also cover use with ursodeoxycholic acid (UDCA), including patients with an inadequate UDCA response.

The patent does not claim elafibranor as a chemical compound, a general pharmaceutical composition, or every use of elafibranor. Its commercial significance is concentrated in the FDA-approved Iqirvo 80 mg PBC regimen and potential generic labeling or prescribing strategies that practice the claimed method.

What does U.S. Patent 12,233,038 claim?

The independent claims are method claims directed to two overlapping treatment concepts:

Claim	Core subject matter
1	Treating PBC by orally administering elafibranor at 70–130 mg per administration, where treatment normalizes ALP
2	Normalizing ALP in a PBC patient by orally administering elafibranor at 70–130 mg per administration

Claims 3–13 narrow claim 1. Claims 14–24 largely repeat the same limitations for claim 2.

The principal claim elements are:

A subject with PBC.
Oral administration.
A composition containing elafibranor or a pharmaceutically acceptable salt.
A dose between 70 mg and 130 mg per administration.
ALP normalization.
Optional once-daily administration.
Optional tablet formulation.
Optional treatment with UDCA or another anti-cholestatic agent.
Optional treatment of a patient with an inadequate response to UDCA.

The independent claims use “comprising,” which generally leaves the method open to additional treatment steps, excipients, therapies, and dosing details unless those additions create a conflict with another claim limitation.

How broad is the 70–130 mg elafibranor dosing range?

The dosing range is broader than the marketed 80 mg dose and includes 120 mg. It captures, on its face, any administration dose above 70 mg and below 130 mg, subject to the interpretation of “between” under applicable claim-construction principles.

The range potentially covers:

80 mg once daily;
120 mg once daily;
intermediate doses such as 90 mg or 100 mg;
split or repeated administration schemes if the dose “per administration” remains within the range;
tablets, capsules, powders, gels, oils, and prolonged-release forms.

The claims do not expressly require a particular tablet strength, tablet size, excipient system, dissolution profile, or pharmacokinetic exposure. They are therefore broader than an 80 mg tablet claim but narrower than a general claim to any elafibranor treatment.

Does the patent cover the FDA-approved Iqirvo regimen?

Yes, based on the supplied claims. The FDA-approved Iqirvo regimen is elafibranor 80 mg administered orally once daily for PBC patients with an inadequate response to UDCA or who are unable to tolerate UDCA. That regimen falls within the central limitations of claims 1, 2, 6, 7, 9, 12, 13, 17, 18, 20, 23, and 24.[2]

The relevant overlap is strongest for:

80 mg per administration;
oral dosing;
once-daily dosing;
PBC;
inadequate response to UDCA;
concurrent UDCA use;
ALP response.

What is the scope of the ALP normalization limitation?

“Normalizes alkaline phosphatase (ALP) level” is a material limitation in independent claims 1 and 2. A practicing method must therefore satisfy both the dosing limitation and the claimed therapeutic outcome.

The claims do not state:

the numerical ALP threshold for normalization;
whether normalization means an ALP value within the laboratory reference range;
whether normalization means normalization from baseline;
whether normalization must be confirmed at a particular time point;
whether a population-level response is sufficient;
whether normalization must be sustained.

Those omissions create interpretive issues. In an infringement dispute, the patent owner would likely rely on the specification, prosecution history, clinical protocols, and ordinary medical meaning to define the result. A generic manufacturer could contest whether the claim requires proof of normalization in each treated patient, a reasonable expectation of normalization, or only administration under a regimen shown to produce the outcome.

The ALP limitation also creates a potential enforcement problem. A physician may prescribe 80 mg elafibranor without knowing whether a particular patient’s ALP will normalize. Method-of-treatment infringement generally turns on performance of the claimed steps, not merely on the product’s availability. The evidentiary burden may therefore differ between a product-label theory, a physician-prescribing theory, and an induced-infringement theory.

What formulations are protected by Patent 12,233,038?

Claims 4, 5, 15, and 16 cover dosage-form categories. The listed forms include:

gel;
oil;
pill;
tablet;
powder;
gel cap;
capsule;
prolonged-release or slow-release galenic forms or devices.

The formulation claims are dependent method claims, not standalone composition claims. They require use of the formulation in the claimed PBC treatment method.

The tablet claims are commercially important because Iqirvo is marketed as an oral tablet. The patent does not appear, from the supplied claims, to require:

a particular tablet coating;
a specific excipient;
a specific particle size;
a defined dissolution rate;
a particular salt or polymorph;
a controlled-release profile;
a fixed tablet composition.

Accordingly, the formulation limitations add relatively little protection against a conventional generic tablet if the generic product is used at the claimed dose for PBC. The principal barrier remains the method-of-use claims.

Does the patent cover combination treatment with UDCA?

Yes. Claims 10–13 and 21–24 cover co-administration with another anti-cholestatic agent and specifically with UDCA.

The strongest combination claims require:

elafibranor at 80 mg per administration;
UDCA;
a PBC patient;
in certain claims, an inadequate response to UDCA.

These claims correspond closely to the clinical and regulatory positioning of elafibranor as an add-on or alternative for patients who do not respond adequately to UDCA or cannot tolerate it.[2]

The UDCA claims may have practical value even if a generic attempts to avoid an all-PBC label. A physician’s documented use of elafibranor together with UDCA in the relevant patient population could fall within the combination claims if the remaining limitations are met.

How do the independent claims compare?

Issue	Claim 1	Claim 2
Disease	PBC	PBC
Drug	Elafibranor or salt	Elafibranor or salt
Route	Oral	Oral
Dose	70–130 mg per administration	70–130 mg per administration
Outcome	Treatment normalizes ALP	Method for normalizing ALP
Drafting focus	Treatment claim	Biomarker-normalization claim
Dependent claims	Claims 3–13	Claims 14–24

Claim 1 is framed as a disease-treatment method and expressly states that treatment normalizes ALP. Claim 2 is framed around the biomarker objective. The two claim groups substantially overlap, which gives the patent owner alternative infringement theories but also creates potential vulnerability to double-patenting, redundancy, claim construction, and written-description challenges depending on the prosecution history.

What is the likely infringement exposure for a generic elafibranor product?

Full PBC label

A generic applicant seeking approval for the same PBC indication and 80 mg once-daily regimen would face substantial method-of-use exposure. The label would likely identify:

PBC;
oral elafibranor;
80 mg once daily;
patients with inadequate UDCA response or UDCA intolerance.

That combination maps directly onto multiple claims.

Skinny-label strategy

A carved-out label could reduce exposure if the generic omits PBC or removes the patented patient population and dosing instructions. The commercial value of a carve-out depends on whether the remaining label still encourages use for PBC and whether prescribing information, promotional conduct, or distribution practices support induced infringement.

A skinny label would be more difficult if the patented method is the only commercially meaningful indication. The FDA regulatory pathway may permit approval of a non-infringing label, but physicians, payors, specialty pharmacies, and electronic prescribing systems can affect real-world substitution and enforcement risk.

Off-label use

Off-label use is not automatically outside the claims. If the method is practiced with the claimed dose, route, disease, and ALP outcome, an off-label use may still satisfy the claim limitations. The practical litigation question would be whether the generic manufacturer caused or encouraged that use.

When does Patent 12,233,038 lose exclusivity?

The patent’s expiration date cannot be established from the claims alone. Patent term depends on the patent’s earliest effective nonprovisional filing date, terminal disclaimers, patent-term adjustment, patent-term extension, and any applicable disclaimer or terminal-expiration provisions.

For a U.S. utility patent, the baseline term is generally 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments.[3] The following dates should be distinguished:

Exclusivity category	Relevance
Patent expiration	Ends enforceable patent rights, subject to term adjustments
FDA regulatory exclusivity	Separate from patent rights
Orphan-drug exclusivity	May restrict approval of the same drug and indication
New chemical entity exclusivity	Applies to the active ingredient and statutory conditions
Pediatric exclusivity	Can add six months to qualifying FDA protections
Patent-term extension	May extend eligible patent rights for regulatory review time

For Iqirvo, FDA approval was granted in June 2024 under the accelerated approval pathway. The approval was based on reductions in ALP and bilirubin, surrogate endpoints associated with disease progression. The FDA label states that clinical benefit remains subject to verification in post-approval studies.[2]

What is the FDA and Orange Book status of Iqirvo?

Iqirvo is the U.S. brand name for elafibranor, marketed by Ipsen Biopharmaceuticals, Inc. The FDA approved Iqirvo in June 2024 for adults with PBC in combination with UDCA when there is an inadequate response to UDCA, or as monotherapy when UDCA is not tolerated.[2]

The product is a small-molecule oral drug, not a biologic. Biosimilar regulation under the Biologics Price Competition and Innovation Act therefore does not apply. Any follow-on product would generally proceed through the abbreviated new drug application pathway as a generic, subject to FDA requirements and applicable patent certifications.[4]

Orange Book treatment is commercially important because listed method-of-use patents can trigger patent certifications and, in some circumstances, a 30-month stay after a timely Paragraph IV notice and patent infringement action. A patent’s enforceability does not depend solely on Orange Book listing, but listing affects ANDA timing and litigation procedure.[4]

The claims supplied are method-of-use claims. Their practical Orange Book value depends on whether the patent is listed against the approved Iqirvo product and whether the listed claims correspond to the approved indication or method of use under FDA listing rules.

What Paragraph IV challenges could target this patent?

An ANDA applicant could challenge the patent by certifying that it is:

invalid;
unenforceable; or
not infringed.

The principal potential invalidity and non-infringement theories would include:

Anticipation

A challenger could rely on earlier clinical or patent publications disclosing elafibranor for PBC at the claimed dose, including ALP improvement or normalization. The key issue would be whether one reference discloses every limitation, including the dose range, oral administration, PBC population, and ALP normalization result.

Obviousness

Obviousness would likely be the most important challenge. Relevant evidence could include:

earlier elafibranor PBC studies;
disclosed 80 mg or 120 mg dosing;
known use of UDCA in PBC;
known ALP as a PBC biomarker;
clinical expectations concerning PPAR-alpha/PPAR-delta agonism;
FDA or clinical-development materials.

The patentee would rely on unexpected clinical results, dose selection, biomarker normalization, safety, and the treatment response in UDCA-inadequate responders.

Written description and enablement

The broad 70–130 mg range may be challenged if the specification does not adequately support the full range or demonstrate ALP normalization across the claimed dose interval. The claims cover multiple formulations and combination regimens, while the disclosed clinical evidence may center on a smaller number of dosage forms and doses.

Indefiniteness

The phrase “normalizes ALP level” may be challenged if the intrinsic record does not establish a reasonably clear boundary. The absence of a numerical definition, time point, baseline requirement, or laboratory standard could become material.

Non-infringement

A generic could argue that:

its label does not instruct the patented PBC use;
its label omits the relevant patient population;
its product is not administered at the claimed dose;
the claim requires an actual ALP-normalization result that is not established;
its formulation or dosing instructions avoid a dependent claim.

How strong is the patent estate for elafibranor?

The supplied patent appears to be a focused use patent rather than a broad foundational patent estate.

Protection category	Apparent position from supplied claims
Chemical composition	Not claimed
Active pharmaceutical ingredient	Not claimed
PBC treatment	Claimed
ALP normalization	Claimed
70–130 mg dosing	Claimed
80 mg dose	Claimed
120 mg dose	Claimed
Once-daily dosing	Claimed
Tablet	Claimed
UDCA combination	Claimed
Manufacturing process	Not claimed
Polymorph or salt characterization	Not claimed
Device or delivery system	Not claimed beyond broad dosage-form language
Biologic exclusivity	Not applicable

The estate is strongest against a generic that copies the FDA-approved 80 mg PBC regimen. It is weaker against:

a non-PBC indication;
a dose outside 70–130 mg;
a use that does not target PBC;
an alternative product with a non-infringing label;
a challenge based on prior art showing the dose and clinical result;
a product launched after a successful invalidity or non-infringement judgment.

The claims do not create a manufacturing barrier. A generic manufacturer could potentially produce elafibranor using an independent process if separate process, composition, polymorph, or formulation patents do not apply.

What patent litigation and settlements affect generic entry?

The supplied information does not establish a filed Paragraph IV action, a settlement agreement, a consent judgment, or a final validity decision involving U.S. Patent 12,233,038. Litigation risk should therefore be assessed from the patent’s current prosecution and Orange Book history, any ANDA notice letters, and federal court docket activity.

A Paragraph IV action would likely focus on whether the patent claims cover the approved 80 mg PBC regimen and whether the ALP-normalization limitation is valid and enforceable. A settlement could include a licensed entry date, a permitted carve-out, a launch contingency, or a non-cash license. No settlement terms are established by the claims supplied.

How does elafibranor compare with competing PBC therapies?

Product	Active ingredient	Regulatory position	Main competitive issue
Iqirvo	Elafibranor	FDA accelerated approval for PBC	Method-of-use patent exposure at 80 mg
Ocaliva	Obeticholic acid	PBC product with major regulatory and safety history	Competing second-line therapy
UDCA products	Ursodeoxycholic acid	Established first-line treatment	Background therapy and combination partner
Seladelpar	Seladelpar	Competing PPAR-directed PBC therapy under development or regulatory review depending on jurisdiction and date	Alternative mechanism and patent estate
Other investigational agents	Various	Clinical-stage	Future competition and separate exclusivity

Elafibranor’s commercial position depends heavily on patients who do not achieve an adequate response to UDCA. Since the patented claims track that population, the method-of-use patent has greater commercial relevance than a broad formulation patent would have.

What generic launch scenarios exist?

Scenario 1: Launch after patent expiry

This is the lowest litigation-risk pathway. The generic can use the approved PBC indication if regulatory exclusivity has also expired.

Scenario 2: Paragraph IV challenge

The applicant challenges validity, enforceability, or infringement and seeks approval before patent expiration. This creates litigation risk and may trigger a statutory approval stay if the patent is properly listed and the statutory conditions are met.

Scenario 3: Carved-out PBC labeling

The applicant removes the patented indication or dosing instructions. This can reduce label-based induced-infringement risk but may sharply reduce commercial value if PBC is the principal indication.

Scenario 4: Non-infringing dose or regimen

A dose outside the claimed range could avoid the literal dose limitation. That strategy may lack regulatory or clinical value because the FDA-approved regimen is 80 mg once daily.

Scenario 5: Authorized generic or license

A license, authorized generic arrangement, or settlement could permit earlier entry under negotiated conditions. No such arrangement is established by the supplied material.

Key Takeaways

U.S. Patent 12,233,038 is a method-of-use patent centered on elafibranor treatment of PBC.
The core dose range is 70–130 mg per administration.
The 80 mg once-daily Iqirvo regimen falls squarely within the supplied claims.
Claims cover ALP normalization, tablets, once-daily dosing, 120 mg dosing, and use with UDCA.
The patent does not, based on the supplied claims, cover the elafibranor molecule, a broad composition of matter, or a manufacturing process.
The ALP-normalization language is central to both infringement scope and validity risk.
The patent creates meaningful Paragraph IV exposure for a generic seeking the same PBC label and 80 mg regimen.
Elafibranor is a small molecule, so biosimilar competition is not relevant; generic ANDA competition is the relevant pathway.
The patent expiration date, Orange Book listing status, terminal disclaimer status, and litigation record are not established by the claim text supplied.
The patent estate appears strongest for the marketed 80 mg PBC use and weaker for manufacturing, formulation, and non-PBC alternatives.

Frequently Asked Questions

Does U.S. Patent 12,233,038 cover elafibranor for all liver diseases?

No. The supplied claims are limited to PBC and do not cover every hepatic disease or every elafibranor indication.

Does taking 80 mg elafibranor automatically infringe the patent?

No. Infringement requires practice of all relevant claim limitations, including the PBC indication, oral administration, dose, and applicable ALP-normalization or treatment requirements.

Is a generic elafibranor required to file a Paragraph IV certification?

Not necessarily. The certification depends on listed patents, their relation to the approved drug, the applicant’s proposed label, and the statutory status of each patent.

Can a generic avoid the patent by using a capsule instead of a tablet?

A capsule may still fall within claims 1 and 2 because those claims do not require a tablet. Avoiding the tablet-dependent claims would not necessarily avoid the independent method claims.

Does UDCA co-administration create a separate patent barrier?

Yes. Claims 10–13 and 21–24 separately address use with another anti-cholestatic agent, particularly UDCA. A regimen can therefore implicate both the elafibranor treatment claims and the combination claims.

References

U.S. Patent No. 12,233,038, claims 1–24. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Iqirvo (elafibranor) prescribing information. FDA.
35 U.S.C. §§ 154, 156. Patent term and patent-term extension provisions. United States Code.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ipsen	IQIRVO	elafibranor	TABLET;ORAL	218860-001	Jun 10, 2024		RX	Yes	Yes	12,233,038	⤷ Start Trial				TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3435996	⤷ Start Trial	301342	Netherlands	⤷ Start Trial
European Patent Office	3435996	⤷ Start Trial	C20250032	Finland	⤷ Start Trial
European Patent Office	3435996	⤷ Start Trial	CA 2025 00035	Denmark	⤷ Start Trial
European Patent Office	3435996	⤷ Start Trial	PA2025535	Lithuania	⤷ Start Trial
European Patent Office	3435996	⤷ Start Trial	LUC50022	Luxembourg	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 12,233,038